Atenolol is a beta-blocker which is beta1-selective, (i.e. acts preferentially on beta1-adrenergic receptors in the heart). Atenolol is without intrinsic sympathomimetic and membrane-stabilising activities and as with other beta-blockers, has negative inotropic effects.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Atenolol is the active ingredient of these drugs:
Brazil
Hong Kong Singapore
Brazil
Ireland
Austria Cyprus Germany
Tunisia
Brazil
Brazil
Brazil
Brazil
Austria
Ireland
Brazil
Tunisia
Hong Kong
Brazil
Spain
Lithuania
Hong Kong
Singapore
Tunisia
Tunisia
Hong Kong
Hong Kong
Hong Kong Singapore
Hong Kong
Australia Hong Kong
Singapore
Hong Kong
Brazil Hong Kong
Hong Kong
Singapore
Singapore
Brazil
Australia
Australia Austria Canada Cyprus Germany
France
Hong Kong
Australia
Hong Kong
Hong Kong
Hong Kong
Cyprus Hong Kong
Cyprus Hong Kong Singapore
Cyprus Singapore
Atenolol is also found within below combination drugs:
ABLOK PLUS , ANGIPRESS CD , ATECOR CT , ATEHEXAL COMP , ATENETIC , ATENIDONE , ATENOCOMP , ATENOLAN-COMP , ATENORESE , BETA-NICARDIA , BETALOR , BLOKIUM-DIU , DIUBLOK , KALTEN , NEATENOL DIU , NIF-TEN , NIFETEX , NIFTEN , PRETENOL C , REVERT , TARGET , TELOL C , TENCHLOR , TENERETIC , TENIF , TENORET , TENORETIC , TRI-NORMIN , TYPOFEN
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):